PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: Therefore, it is on record that olaparib, niraparib, and rucaparib have clinically proven successful in improving progression-free survival rates among patients suffering from advanced ovarian cancer [2].Besides treating BRCA-mutated tumours, even more, advanced forms of therapy utilizing PARP inhibitors have been reported to be effective against a greater number of patients who have HRD [3].